BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND AXIN1, LA16c-314G4_3, 8312, ENSG00000103126, O15169, AXIN, MGC52315
32905 results:

  • 1. Circular RNA circMAN1A2 promotes ovarian cancer progression through the microRNA-135a-3p/IL1RAP/TAK1 pathway.
    Li B; Hu C; Zhao D; Nie M; Wang X
    PeerJ; 2024; 12():e16967. PubMed ID: 38680890
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Effects of Resveratrol on In Vivo ovarian cancer Cells Implanted on the Chorioallantoic Membrane (CAM) of a Chicken Embryo Model.
    Chitcholtan K; Singh M; Tino A; Garrill A; Sykes P
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673959
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Synthesis of Estrone Heterodimers and Evaluation of Their In Vitro Antiproliferative Activity.
    Bózsity N; Nagy V; Szabó J; Pálházi B; Kele Z; Resch V; Paragi G; Zupkó I; Minorics R; Mernyák E
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673860
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Using Portuguese BRCA pathogenic variation as a model to study the impact of human admixture on human health.
    Andaluz S; Zhao B; Sinha S; Lagniton PNP; Costa DA; Ding X; Brito M; Wang SM
    BMC Genomics; 2024 Apr; 25(1):416. PubMed ID: 38671360
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. High-Grade Serous ovarian cancer during Pregnancy: From Diagnosis to Treatment.
    Vivod G; Merlo S; Kovacevic N
    Curr Oncol; 2024 Apr; 31(4):1920-1935. PubMed ID: 38668047
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Exceptional lymph node recurrence of an unusual ovarian tumor 16 years later: a case report.
    Sakhri S; Slimane M; Bouaziz H; Khessairi N; Boujelbene N; Ben Dhiab T
    J Med Case Rep; 2024 Apr; 18(1):217. PubMed ID: 38654310
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
    Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
    BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Granulosa cell tumor of the ovary: a series of 6 cases.
    da Costa REAR; Silva MCA; Cavalcante ECX; Branco ROC; Dos Reis CA; Vieira SC
    Pan Afr Med J; 2024; 47():58. PubMed ID: 38646138
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
    Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
    Fu W; Feng Q; Tao R
    Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Primary lymphoma of the female genital tract masquerading as gynecological malignancy.
    Shi S; Li W; Ni G; Ding J; Liu Y; Wu H; Zhang Z; Ding Z
    BMC Womens Health; 2024 Apr; 24(1):247. PubMed ID: 38637800
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant ovarian cancer: Final Overall Survival and Biomarker Analyses.
    Konstantinopoulos PA; Cheng SC; Lee EK; da Costa AABA; Gulhan D; Wahner Hendrickson AE; Kochupurakkal B; Kolin DL; Kohn EC; Liu JF; Penson RT; Stover EH; Curtis J; Sawyer H; Polak M; Chowdhury D; D'Andrea AD; Färkkilä A; Shapiro GI; Matulonis UA
    JCO Precis Oncol; 2024 Apr; 8():e2300635. PubMed ID: 38635934
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.
    Li N; Jin S; Wu J; Ji H; Du C; Liu B
    PLoS One; 2024; 19(4):e0299504. PubMed ID: 38635517
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Rates of paclitaxel hypersensitivity reactions using a modified Markman's infusion protocol as primary prophylaxis.
    Symons R; Heath F; Duggan J; Bui KT; Byun L; Friedlander M; Lee YC
    Support Care Cancer; 2024 Apr; 32(5):292. PubMed ID: 38632132
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Imaging for local recurrence of breast cancer.
    Schlaiss T; Bott L; Herbert SL; Bartmann C; Kiesel M; Salmen J; Sauer ST; Christner SA; Petritsch B; Grunz JP; Woeckel A; Löb S; Diessner J
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):200. PubMed ID: 38627285
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Gonadoblastoma: Clinicopathological study and literature review of 3 cases].
    Bao ML; Li X; Chen G; Li H; Chen W; Li HX
    Zhonghua Nan Ke Xue; 2023 Jul; 29(7):634-638. PubMed ID: 38619412
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A New Model Including AMH Cut-off Levels to Predict Post-treatment ovarian Function in Early Breast cancer: A Prospective Cohort Study.
    Omranipour R; Ahmadi-Harchegani F; Saberi A; Moini A; Shiri M; Jalaeefar A; Arian A; Seifollahi A; Madani M; Eslami B; Alipour S
    Arch Iran Med; 2024 Feb; 27(2):96-104. PubMed ID: 38619033
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Cytotoxic activity and cell specificity of a novel LHRH peptide drug conjugate, D-Cys6-LHRH vedotin, against ovarian cancer cell lines.
    Vankadara S; Ke Z; Wang S; Foo SY; Gunaratne J; Lee MA; Koh X; Chia CSB
    Chem Biol Drug Des; 2024 Apr; 103(4):e14516. PubMed ID: 38618710
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine.
    Elshami M; Jaber I; Alser M; Al-Slaibi I; Jabr H; Ubaiat S; Tuffaha A; Khader S; Khraishi R; Arafeh ZA; Al-Madhoun S; Alqattaa A; Yaseen A; El Hadi AA; Barhoush O; Hijazy M; Eleyan T; Alser A; Hziema AA; Shatat A; Almakhtoob F; Mohamad B; Farhat W; Abuamra Y; Mousa H; Adawi R; Musallam A; Albarqi SI; Abu-El-Noor N; Bottcher B
    BMC Public Health; 2024 Apr; 24(1):1027. PubMed ID: 38609950
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
    Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 1646.